Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status
BackgroundHeart failure with preserved ejection fraction (HFpEF), a major cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM), is frequently coexisted with obesity, poor glycemic, blood pressure (BP), and/or lipid control. We aimed to investigate the associations of nonalcoholic fatty liver disease (NAFLD) and its advanced fibrosis with HFpEF according to obesity, glycated hemoglobin A1c (HbA1c), BP, and low-density lipoprotein cholesterol (LDL-C) goal achievement status in T2DM patients.MethodsA total of 2,418 T2DM patients who were hospitalized were cross-sectionally assessed. Liver fibrosis was evaluated by non-invasive biomarkers. Logistic regression analysis was used to evaluate the independent and combined associations of fibrosis status and diabetic care goal attainments with HFpEF risk.ResultsSimple steatosis was not associated with HFpEF risk compared with patients without steatosis, while advanced liver fibrosis was found to have significantly higher odds for HFpEF risk (odds ratio,1.59; 95% confidence interval, 1.22-2.08). Advanced fibrosis in NAFLD was significantly associated with an increased risk of HFpEF, regardless of obesity status, HbA1c, BP, and LDL-C goal achievement status. P values for the interactions between fibrosis status and HbA1c control status, fibrosis status and BP control status, fibrosis status and LDL-C control status, and fibrosis status and body mass index (BMI) status on HFpEF risk were 0.021, 0.13, 0.001, and 0.23, respectively.ConclusionIn patients with T2DM, advanced hepatic fibrosis was significantly associated with HFpEF risk, irrespective of obesity status, HbA1c, BP, and LDL-C goal attainment status. Further, HbA1c and LDL-C goal attainment status modified this association.
基金:
This study was supported by the Bethune Charitable Foundation 2020 (to TD) and Sen-Mei China Diabetes Research Fund Z-2017-26-1902 (to ZL).; Bethune Charitable Foundation [Z-2017-26-1902]; Sen-Mei China Diabetes Research Fund
第一作者单位:[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Hubei, Peoples R China[2]Branch Natl Clin Res Ctr Metab Dis, Wuhan, Hubei, Peoples R China[3]Deyang Peoples Hosp, Dept Clin Nutr, Deyang, Sichuan, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan, Hubei, Peoples R China[2]Branch Natl Clin Res Ctr Metab Dis, Wuhan, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
Jiang Wangyan,Liu Zhelong,Liu Shaohua,et al.Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status[J].FRONTIERS IN ENDOCRINOLOGY.2023,14:doi:10.3389/fendo.2023.1183075.
APA:
Jiang, Wangyan,Liu, Zhelong,Liu, Shaohua&Du, Tingting.(2023).Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status.FRONTIERS IN ENDOCRINOLOGY,14,
MLA:
Jiang, Wangyan,et al."Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status".FRONTIERS IN ENDOCRINOLOGY 14.(2023)